The Food and Drug Administration today released draft guidance for assessing risk evaluation and mitigation strategies. FDA may require a REMS before approving certain drugs, including biologics, to help ensure its benefits outweigh its risks. FDA Commissioner Scott Gottlieb, M.D., said the guidance provides a framework for companies to develop an assessment plan when they develop a REMS program to improve the quality of the information used to assess the program’s effectiveness and provide post-market evidence that the REMS is meeting its risk mitigation goals. “We need to make sure that the REMS are achieving their public health goals, and that we’re designing and implementing these approaches in ways that minimize burdens to patients and providers,” he said.

Related News Articles

Headline
Beginning with open enrollment for plan year 2020, the Centers for Medicare…
Headline
Currently available public hospital quality rating systems frequently offer conflicting results, which may mislead stakeholders relying on the ratings to…
Headline
The Centers for Disease Control and Prevention has released the first in a new series of free online training courses to help health care organizations prevent…
Headline
Patients receiving either of two investigational treatments for Ebola in the Democratic Republic of the Congo had a greater chance of survival than those…
Chairperson's File
Often quietly and out of the public eye, the vital work of advancing health in America happens on many fronts.
Headline
The Department of Health and Human Services offers a resource to help health care providers and others prepare for and respond to mass violence events such as…